The United States Food and Drug Administration (US FDA) has approved VYKATâ„¢ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...